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The general affinity of the sarcoplasmic reticulum (SR) Ca2+-ATPase was examined for three different classes of
vanadium coordination complexes including a vanadium(V) compound, pyridine-2,6-dicarboxylatodioxovanadium(V)
(PDC-V(V)), and two vanadium(IV) compounds, bis(maltolato)oxovanadium(IV) (BMOV), and an analogue of
amavadine, bis(N-hydroxylamidoiminodiacetato)vanadium(IV) (HAIDA-V(IV)). The ability of vanadate to act either
as a phosphate analogue or as a transition-state analogue with enzymes’ catalysis phosphoryl group transfer
suggests that vanadium coordination compounds may reveal mechanistic preferences in these classes of enzymes.
Two of these compounds investigated, PDC-V(V) and BMOV, were hydrolytically and oxidatively reactive at neutral
pH, and one, HAIDA-V(IV), does not hydrolyze, oxidize, or otherwise decompose to a measurable extent during
the enzyme assay. The SR Ca2+-ATPase was inhibited by all three of these complexes. The relative order of
inhibition was PDC-V(V) > BMOV > vanadate > HAIDA-V(IV), and the IC50 values were 25, 40, 80, and 325 µM,
respectively. Because the observed inhibition is more potent for PDC-V(V) and BMOV than that of oxovanadates,
the inhibition cannot be explained by oxovanadate formation during enzyme assays. Furthermore, the hydrolytically
and redox stable amavadine analogue HAIDA-V(IV) inhibited the Ca2+-ATPase less than oxovanadates. To gauge
the importance of the lipid environment, studies of oxidized BMOV in microemulsions were performed and showed
that this system remained in the aqueous pool even though PDC-V(V) is able to penetrate lipid interfaces. These
findings suggest that the hydrolytic properties of these complexes may be important in the inhibition of the calcium
pump. Our results show that two simple coordination complexes with known insulin enhancing effects can invoke
a response in calcium homeostasis and the regulation of muscle contraction through the SR Ca2+-ATPase.
Introduction
Vanadium oxoanions are known to inhibit or stimulate
many enzymes1–7 such as the membrane-bound E1-E2
Ca2+-ATPase.8,9 Because vanadate can act as a transition-
state analogue as well as a phosphate analogue, the details
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of the mode of inhibition are often not clear and inhibition
of organic vanadium complexes can be of mechanistic
importance to sort out the different modes of action.1,2,6 The
active site of the Ca2+-ATPase, a calcium pump, contains
an aspartyl residue that is phosphorylated during the catalytic
cycle, thereby forming an acyl phosphate anhydride.10 The
mechanism of the inhibition by vanadate is attributed to the
blocking by vanadate of the formation of the E2 conforma-
tion of the Ca2+-ATPase from the sarcoplasmic reticulum
(SR).8 How vanadate oligomers interact with the SR calcium
pump and inhibit its activity have been investigated.9,11 For
instance, decameric vanadate species (V10) in functional SR
vesicles (absence of calcium ionophore) inhibit calcium
accumulation coupled with ATP hydrolysis, whereas mon-
omeric vanadate (V1) has no effects.11 Moreover, other
vanadate species, for example tetrameric vanadate species
(V4), may also have an implicit effect on H+ ejection
associated with calcium translocation.9 In fact, the SR
calcium pump has proven to be an excellent model to study
the effects of vanadium in Ca2+ homeostasis, particularly in
instances where some oxovanadates have been found to
disrupt energy coupling and enzyme turnover.9 Recently,
decreased SR calcium pump activity was reported under
specific conditions associated with diabetes that could result
in impaired cardiac relaxation.12
Many vanadium compounds are known to have insulin-
like or insulin-enhancing effects on several animal model
systems.6,13–16 Studies have been carried out with simple salts
and coordination complexes of vanadium in oxidation states
III, IV,6,13,14,16 and V.6,15,16 In addition to the animal studies,
a range of studies was also carried out in several cellular
systems, which probed the activity of specific classes of
vanadium compounds and how these compounds act.17–19
In such biological studies, the nature of the active vanadium
compound cannot readily be identified, and consideration of
chemical and metabolic processing is difficult.6,15,16 How-
ever, various approaches to address this problem have
provided some further insight as to the biological activity
of these compounds.5–7,16,20 Information on how effectively
specific compounds inhibit isolated enzymes is important for
consideration of their mode of actions in cells and animals.6
A range of studies of a few vanadium compounds on
isolated enzyme systems have been reported where the
species exerting the effects can be more rigorously
tracked.5,21,22 Most of these studies were carried out with
phosphatases and kinases,21,22 but some studies with proteins
in other metabolic pathways5,23,24 including the Ca2+-ATPase
are available.25 Vanadium complexes are generally found
to be inhibitors, although the potency of the compounds
varies widely from millimolar to nanomolar efficacy.6 The
effects of oxovanadates have been reported on a range of
isolated classes of enzymes such as phosphorylases and
dehydrogenases, and include application of vanadate as a
structural probe in X-ray diffraction studies of protein-
vanadate complexes.26 In this work, we consider the effects
of three very different classes of vanadium compounds, two
of which are known to induce insulin-enhancing effects16,27
and a third class that is a well-known analogue of a
vanadium-containing natural product.28–31 The vanadium-
containing natural product is very different from the other
two vanadium compounds with regard to structure and
properties (Figure 1).
Conversion of vanadium complexes to simple vanadate
oligomers5,16 and salts in the biological system complicate
the interpretation of the effects of the compounds and is not
generally considered. Even in the micromolar range, oxo-
vanadates can induce specific responses in enzymes such as
phosphohydrolases5,32,33 and, therefore, effects observed in
vivo20,34–38 may be, in part, due to the action of species such
as decavanadate (V10),38 vanadate monomer,5 or vanadyl
(9) Aureliano, M.; Madeira, V. M. C. In Vanadium in the EnVironment,
Part 1: Chemistry and Biochemistry; Nriagu, J. O., Ed.; John Wiley
& Sons, Inc.: New York, 1998, pp 333-357.
(10) de Meis, L.; Vianna, A. L. Annu. ReV. Biochem. 1979, 48, 275–92.
(11) Aureliano, M.; Madeira, V. M. Biochim. Biophys. Acta 1994, 1221,
259–271.
(12) Bidasee, K. R.; Zhang, Y.; Shao, C. H.; Wang, M.; Patel, K. P.; Dincer,
U. D.; Besch, H. R., Jr. Diabetes 2004, 53, 463–473.
(13) Sakurai, H. Chem. Rec. 2002, 2, 237–248.
(14) Melchior, M.; Rettig, S. J.; Liboiron, B. D.; Thompson, K. H.; Yuen,
V. G.; McNeill, J. H.; Orvig, C. Inorg. Chem. 2001, 40, 4686–4690.
(15) Thompson, K.; Orvig, C. J. Chem. Soc., Dalton Trans. 2000, 2885–
2892.
(16) Buglyo, P.; Crans, D. C.; Nagy, E. M.; Lindo, R. L.; Yang, L.; Smee,
J. J.; Jin, W.; Chi, L.-H.; Godzala, M. E.; Willsky, G. R. Inorg. Chem.
2005, 44, 5416–5427.
(17) Rehder, D.; Pessoa, J. C.; Geraldes, C. F. G. C.; Castro, M. M. C. A.;
Kabanos, T.; Kiss, T.; Meier, B.; Micera, G.; Pettersson, L.; Rangel,
M.; Salifoglou, A.; Turewl, I.; Wang, D. J. Biol. Inorg. Chem. 2002,
7, 384–396.
(18) Etcheverry, S. B.; Cortizo, A. M. In Vanadium in the EnVironment.
Part 1: Chemistry and Biochemistry; Nriagu, J. O., Ed.; John Wiley
& Sons, Inc.: New York, 1998, pp 359-394.
(19) Cortizo, A. M.; Bruzzone, L.; Molinuevo, S.; Etcheverry, S. B.
Toxicology 2000, 147, 89–99.
(20) Thompson, K. H.; Liboiron, B. D.; Hanson, G. R.; Orvig, C. In
Medicinal Inorganic Chemistry; Sessler, J. L., Doctrow, S. R.,
McMurry, T. J., Lippard, S. J., Eds.: ACS Symposium Series, Vol.
903, Chap. 21: 385-399, American Chemical Society: Washington,
DC, 2005.
(21) Posner, B. I.; Faure, R.; Burgess, J. W.; Bevan, A. P.; Lachance, D.;
Zhang-Sun, G.; Fantus, I. G.; Ng, J. B.; Hall, D. A.; Lum, B. S.;
Shaver, A. J. Biol. Chem. 1994, 269, 4596–4604.
(22) Crans, D. C.; Keramidas, A. D.; Drouza, C. Phosphorus, Sulfur, Silicon
Relat. Elem 1996, 109-110, 245–248.
(23) Mustafi, D.; Bekesi, A.; Vertessy, B. G.; Makinen, M. W. Proc. Natl.
Acad. Sci. U.S.A. 2003, 100, 5670–5675.
(24) Ou, H. S.; Yan, L. M.; Mustafi, D.; Makinen, M. W.; Brady, M. J.
J. Biol. Inorg. Chem. 2005, 10, 874–886.
(25) Aureliano, M.; Tiago, T.; Gândara, R. M.; Sousa, A.; Moderno, A.;
Kaliva, M.; Salifoglou, A.; Duarte, R. O.; Moura, J. J. J. Inorg.
Biochem. 2005, 99, 2355–2361.
(26) Davies, D. R.; Hol, W. G. J. FEBS Lett. 2004, 577, 315–321.
(27) McNeill, J. H.; Yuen, V. G.; Hoveyda, H. R.; Orvig, C. J. Med. Chem.
1992, 35, 1489–1491.
(28) Garner, C. D.; Armstrong, E. M.; Berry, R. E.; Beddoes, R. L.;
Collison, D.; Cooney, J. J.; Ertok, S. N.; Helliwell, M. J. Inorg.
Biochem. 2000, 80, 17–20.
(29) Anderegg, G.; Koch, E.; Bayer, E. Inorg. Chim. Acta 1987, 127, 183–
188.
(30) Bayer, E.; Koch, E.; Anderegg, G. Angew. Chem., Int. Ed. Engl. 1987,
26, 545–546.
(31) Kneifel, H.; Bayer, E. J. Am. Chem. Soc. 1986, 108, 3075–3077.
(32) Tiago, T.; Aureliano, M.; Gutierrez-Merino, C. Biochemistry 2004,
43, 5551–5561.
(33) Tiago, T.; Aureliano, M.; Moura, J. J. J. Inorg. Biochem. 2004, 98,
1902–1910.
(34) Aureliano, M.; Joaquim, N.; Sousa, A.; Martins, H.; Coucelo, J. M.
J. Inorg. Biochem. 2002, 90, 159–165.
(35) Willsky, G. R.; White, D. A.; McCabe, B. C. J. Biol. Chem. 1984,
259, 13273–13281.
Aureliano et al.
5678 Inorganic Chemistry, Vol. 47, No. 13, 2008
cation.5,23,24,39 Combining biochemical kinetic studies with
analysis by 51V NMR spectroscopy,9,11 it is possible to
correlate inhibition with the presence of specific vanadate
species as has previously been reported.5,9,11,23,24,26
In the present study, the effects of three vanadium
complexes, namely pyridine-2,6-dicarboxylatodioxovanadi-
um(V) (PDC-V(V)),16 bis(maltolato)oxovanadium(IV)
(BMOV)27 and an analogue of amavadine, bis(N-hydroxy-
lamidoiminodiacetato)vanadium(IV) HAIDA-V(IV),28 on
SR Ca2+-ATPase activity were evaluated (Figure 1). The two
complexes known to interconvert to other species at neutral
pH and in the presence of oxygen were studied to examine
the extent of conversion of these systems to other vanadi-
um(V) species and to determine whether the resulting species
interact with the SR calcium pump. The most-potent inhibi-
tion observed for the PDC-V(V) complex exceeded that of
vanadate solutions reported previously11 and provided com-
pelling evidence that the observed inhibition cannot simply
be due to conversion of the complex to oxovanadate.6
Materials and Methods
Reagents. Reagent-grade chemicals were used to prepare buffers.
Ammonium metavanadate was purchased from Riedel-de Haën.
ATP (vanadium free) was supplied by Sigma. All other reagents
were of biochemical analysis grade from BDH, Merck, or Sigma.
The synthesis of the vanadium complexes was performed as
described previously for pyridine-2,6-dicarboxylatodioxovanadi-
um(V) PDC-V(V)),16 bis(maltolato)oxovanadium(V) (BMOV)40
and the simple amavadine analogue bis(N-hydroxylamidoimino-
diacetato)vanadium(IV), HAIDA-V(IV).28,41 The chemistry of
these systems is well-described and predicts that a minor fraction
of the PDC-V(V) complex would retain its structural identity
during the enzyme assay;16 however, a larger fraction of
BMOV6,7,14 and all of the amavadine analogue remain in their
original form.6,7,29,30 These predictions are based on reports that
the PDC-V(V) complexes are hydrolyzed and reduced at neutral
pH and under physiological conditions6,7 BMOV is known to
oxidize in solution6,7,14 but amavadine is stable.6,7,29,30
Stock solutions (9 mM) of vanadium complexes were prepared
from pyridine-2,6-dicarboxylatodioxovanadium(V) (PDC-V(V)),
bis(maltolato)oxovanadium(IV) (BMOV), and amavadine-analogue
HAIDA-V(IV) in water or in media containing 25 mM HEPES
(2-(4-(2-hydroxyethyl)-1-piperazinyl)ethanesulfonic acid), pH 7.0,
and 0.1 M KCl, immediately prior to use in studies.
Preparation of Sarcoplasmic Reticulum Vesicles. Sarcoplas-
mic reticulum vesicles (SRV) were prepared from skeletal rabbit
muscles as described elsewhere.11,42 For activity measurements,
the SR were isolated from rabbits that had been subjected to a
48 h starvation diet43 to decrease the amount of glycogen
phosphorylase associated with the SR membranes. Isolated SR
vesicles suspended in 0.1 M KCl, 10 mM HEPES (pH 7.0) were
diluted 1:1 with 2.0 M sucrose and frozen in liquid nitrogen
prior to storage at -80 °C. For SR-vesicle preparations used in
NMR studies, sucrose was omitted from sample preparations
because sucrose is known to form complexes with vanadate.9,11
Protein concentration was determined spectrophotometrically at
280 nm by the Biuret method, using bovine serum albumin as a
standard44 and in the presence of 1% of sodium dodecyl sulfate.45
The percentage of each protein present in the SR-vesicle
preparations was determined through densitometry analysis of
sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis
(7.5% acrylamide). The SR Ca2+-ATPase analyzed by SDS-
polyacrylamide gel electrophoresis was at least 70% of the total
protein in the SR-vesicles. The SERCA 1, sarcoplasmic, or
endoplasmic reticulum Ca2+-ATPase 1 was found as the
predominant isoform in our SR preparations.45
NMR Measurements. Vanadium-51 (51V) nuclear magnetic
resonance spectroscopy measurements on vanadium complex solu-
tions were recorded on a Bruker AM-400 MHz or a Varian Inova
400 MHz spectrometer using a 90° pulse angle. Chemical shift
values are referenced to a VOCl3 (0.00 ppm) standard. The relative
areas of vanadium(V) resonances were integrated, and the line
widths were obtained by subtracting the 20 Hz line broadening used
in the data processing. The concentrations of vanadium(V) species
were calculated from the fractions of the total integrated areas
observed in the recorded spectra as described elsewhere.5,11
The 51V NMR spectra of solutions of vanadium complexes
(PDC-V(V) and oxidized BMOV) were obtained at several
concentrations in the reaction medium, containing 0.1 M KCl, 5.0
mM MgCl2, 50 µM CaCl2, and 500 µM ATP in 25 mM (pH 7.0)
HEPES. Spectra of the complexes were obtained in the reaction
medium at ambient temperature, in the absence or presence of SR
preparations (up to 10 mg/mL). The spectral parameters for these
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Figure 1. Molecular structures of PDC-V(V), BMOV, HAIDA-V(IV),
and [VO2(ma)2]-.
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solutions were spectral width 40 355 Hz, accumulation time 0.05 s,
number of transients between 12 000 and 25 000, and a relaxation
delay of 0.01 s. These parameters were held constant for all
quantitative measurements.11
EPR Measurements. EPR spectra were obtained with a con-
ventional X-band Bruker EMX 6/1 spectrometer equipped with a
Bruker ER4116DM dual mode cavity. An Oxford ESR900 continu-
ous-flow cryostat was used. The spectra of frozen solutions were
acquired at 77 K using 0.2 mL of samples. Typical measurement
conditions for CW-EPR were field modulation frequency, 100 kHz;
modulation amplitude, 10 G; receiver gain, 5.02 × 104; time
constant, 40.96 ms; sweep time 167.77 s; microwave power, 0.2
mW; and the number of scans, 4.
ATP Hydrolysis By Calcium Pump. Steady-state assays of the
sarcoplasmic reticulum Ca2+-ATPase were measured spectropho-
tometrically at 25 °C, using the coupled enzyme pyruvate kinase/
lactate dehydrogenase assay45 under the following conditions: 25
mM HEPES (pH 7.0), 100 mM KCl, 5 mM MgCl2, 50 µM CaCl2,
2.5 mM ATP, 0.42 mM phosphoenolpyruvate, 0.25 mM NADH,
18 IU lactate dehydrogenase, and 7.5 IU pyruvate kinase. The
experiments were initiated after the addition of 10 µg/ml protein
in the presence of 4% (w/w) of calcium ionophore A23187 and
followed for 10 min. Vanadium complex solutions were added to
the medium prior to protein addition. The absorbance of the
vanadium complexes had no effect on the observation of the rapid
decrease in absorbance at 340 nm upon addition of 40 µM ADP
after the assay.
Model Microemulsion Preparation. The microemulsion model
system (reverse micelles, RMs, AOT/isooctane/H2O) were prepared
by pipetting the solution of [VO2(ma)2]- (the oxidized form of
BMOV, Figure 1)40 at pH 4.4, 5.9, and 7.6, into aliquots of the
0.500 M AOT (sodium bis(2-ethylhexyl) sulfosuccinate) stock
solution in isooctane. [VO2(ma)2]- was prepared from 60 mM
NaVO3 and 120 mM maltol (3-hydroxy-2-methyl-4-pyrone) to form
the 1:2 complex in D2O as described previously.40 All samples were
mixed by shaking prior to spectroscopic measurements, and the
resulting solutions were transparent. Dynamic light scattering
experiments were performed to demonstrate that RMs form in
solution and to measure their size and polydispersity (DynaPro-
MSTC) as reported previously.46
Results and Discussion
We find that the addition of the three different vanadium
complexes, PDC-V(V), BMOV, and HAIDA-V(IV), has
markedly different effects from oxovanadate on the activity
of the calcium ATPase from the sarcoplasmic reticulum. The
ATPase activity is measured by coupling pyruvate dehydro-
genase/lactate dehydrogenase oxidation of NADH and plotted
as a percentage activity compared to the observed activity
in the absence of test compound. All three vanadium
compounds inhibit the ATP hydrolysis, with the PDC-V(V)
inhibiting the hydrolysis at lower concentrations. The 50%
inhibition level was observed for PDC-V(V) and BMOV
at 25 µM and 40 µM, respectively (part A of Figure 2). The
amavadine analogue HAIDA-V(IV) also inhibits the enzy-
matic activity but to a lower extent, with an IC50 value of
325 µM (part B of Figure 2). The inhibition is observed at
compound levels higher than typically administered in animal
studies;6,15,20,40 however, it is not uncommon that the
inhibition level of isolated enzymes does not correspond with
inhibition observed in cells.
No effects were observed on the basal activity recorded
just before the addition of the calcium ionophore. This
observation suggests that, at the concentration of compounds
studied, the complexes do not uncouple the calcium ac-
cumulation from the ATP hydrolysis of the native vesicles
from the sarcoplasmic reticulum calcium pump. Recent
studies demonstrated that vanadium citrate complexes are
weak inhibitors of the calcium ATPase with an IC50 of 500
µM.25 By comparison, under identical experimental condi-
tions as used here, a metavanadate solution results in an IC50
value of 80 µM (data not shown). Therefore, we conclude
that the BMOV and PDC-V(V) complexes are stronger
inhibitors of the calcium pump than the most-potent oxo-
vanadates. Given these observations, we investigated the
interaction of the vanadium species that existed under the
assay conditions in the presence of the SR preparation.
The 51V-NMR spectra of the PDC-V(V) complex in the
medium shows a single resonance at -534 ppm (Figure 3)
with a half-line width of 120 ( 10 Hz. This chemical shift(46) Maitra, A. J. Phys. Chem. 1984, 88, 5122–5125.
Figure 2. Effects of (A) BMOV (O) and PDC-V(V) (b), (B) HAIDA-
V(IV) on Ca2+-ATPase activity by the SR calcium pump. Sarcoplasmic
reticulum vesicles, 10 µg/ml, were incubated during 5 min at 25 °C in a
medium containing 25 mM HEPES (pH 7.0), 100 mM KCl, 5.0 mM MgCl2,
50 µM CaCl2, 0.42 mM phosphoenolpyruvate, 0.25 mM NADH, and the
concentration of the vanadium complexes in (A) (PDC-V(V) (b) and
BMOV (O)) and (B) (HAIDA-V(IV)) was varied as indicated on the
abscissa. After the incubation, 18 IU lactate dehydrogenase plus 7.5 IU
pyruvate kinase, 0.4 µg /ml A23187, and 2.5 mM ATP were added to the
medium. The ATPase activity was measured as indicated in the Materials
and Methods section. Experimental values are means of at least 3 different
experiments with 3 different sarcoplasmic reticulum vesicles preparations.
In most experiments, the SD values are covered by the symbol.
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is close to the -531 ppm reported for the PDC-V(V)
complex in aqueous solution16 and demonstrates that this is
the species present under assay conditions. Addition of
sarcoplasmic reticulum vesicles (up to 10 mg/mL) to the
PDC-V(V) solution in the reaction medium results in
significant line broadening (up to 300 Hz) and decrease in
intensity of the 51V-NMR signal with increasing protein
concentration (parts B and C of Figure 3). Signal broadening
has previously been observed when vanadium derivatives
interact with proteins.47–49 There was no significant change
in chemical shift in the spectra as protein concentration was
increased. The solution was very sensitive to temperature
and vanadate oligomers formed when slight-heating was
used during solution preparation. In this case, besides the
resonance at -534 ppm, signals were observed at -560,
-574, and -578 ppm due to monomeric (V1), dimeric (V2),
and to cyclic tetrameric (V4) vanadate species (data not
shown), respectively. Because sucrose is often present in the
SR preparations, spectra were acquired in the presence of
sucrose. No broadening of the NMR signal was detected by
the addition of the equivalent amounts of sucrose to those
present in the SR preparations (data not shown). These results
indicate that the observed line broadening is due to vanadium
complex interaction with the SR preparation.
The possibility that signal broadening may be due to
components in the SR-vesicles other than the calcium pump
was considered. Significant amounts of glycogen phospho-
rylase (16%) and calsesquestrin (10%) besides others proteins
(as observed by SDS-PAGE gel electrophoreses) may be
present in these preparations. Previous studies with glycogen
phosphorylase indicate that this enzyme interacts with
vanadate; however, the interaction is not extensive (unpub-
lished data50). Although vanadate does interact with other
proteins, significant amounts of protein must generally be
present to result in the observed line broadening.5,23,24,51,52
Therefore, although these studies do not rule out that these
interactions with the vanadium complexes exist, the mag-
nitude of the observed response would require a protein with
an exceedingly strong affinity for vanadate to exhibit the
observed effect.
The possibility that the line broadening is caused by
association of the compounds with the lipid arrangement
(assembly) in the SR-vesicle was also considered. We have
previously observed that PDC-V(V) is able to penetrate a
model lipid surface.51 In the model system, line broadening
of the PDC-V(V) signal was attributed to immobilization
of the compound because proton 2D NOESY spectroscopy
studies demonstrated that the protons on the aromatic ring
were near the lipid tail group, and thus the complex
penetrates the nonpolar layer.51,52 In the studies with the SR-
vesicle, line broadening may also occur because of this type
of interaction. However, because the concentration of lipid
in the assay is small and the vanadium complex is in large
excess, the lipid interaction in these preparations is not likely
able to support the 4 mM PDC-V(V) complex used in these
studies. These considerations are consistent with attributing
line broadening of the complex signal primarily to interaction
with the Ca2+-ATPase.
The BMOV solutions contain vanadium(IV) species
observable by EPR spectroscopy (data not shown) consistent
with reports describing the solution properties of this
compound.40 In addition, BMOV is known to oxidize in the
presence of oxygen and form the corresponding V(V)-maltol,
[VO2(ma)2]- complex (part A of Figure 4).40,53 The oxidation
of BMOV under the assay conditions described in this work
immediately result in the formation of [VO2(ma)2]- (parts
B and C of Figure 4); however, even after 24 h, less than
50% of BMOV oxidized in cell-free samples. It is known
that such oxidation is much less after administration of
BMOV to cells and animals.40,54 Studies, using 51V NMR
spectroscopy, were conducted to monitor how much of the
BMOV oxidized to form [VO2(ma)2]- complex and oxo-
vanadates and to demonstrate that placement in the assay
medium did not impact the complex otherwise. The spectrum
presented in Figure 4 has a signal at -495 ppm that is(47) Butler, A.; Danzitz, M. J.; Eckert, H. J. Am. Chem. Soc. 1987, 109,
1864–1865.
(48) Stankiewicz, P. J.; Gresser, M. J.; Tracey, A. S.; Hass, L. F.
Biochemistry 1987, 26, 1264–1269.
(49) Wittenkeller, L.; Lin, W.; Diven, C.; Ciaccia, A.; Wang, F.; Mota de
Freitas, D. Inorg. Chem. 2001, 40, 1654–1662.
(50) Drueckhammer, D. G.; Durrwachter, J. R.; Pederson, R. L.; Crans,
D. C.; Daniels, L.; Wong, C.-H. J. Org. Chem. 1989, 54, 70–77.
(51) Crans, D. C.; Rithner, C. D.; Baruah, B.; Gourley, B. L.; Levinger,
N. E. J. Am. Chem. Soc. 2006, 128, 4437–4445.
(52) Crans, D. C.; Baruah, B.; Levinger, N. E. Biomed. Pharmacother.
2006, 60, 174–181.
(53) Elvingson, K.; González Baró, A.; Pettersson, L. Inorg. Chem. 1996,
35, 3388–3393.
(54) Amin, S. S.; Cryer, K.; Zhang, B.; Dutta, S. K.; Eaton, S. S.; Anderson,
O. P.; Miller, S. M.; Reul, B. A.; Brichard, S. M.; Crans, D. C. Inorg.
Chem. 2000, 39, 406–416.
Figure 3. 51V-NMR spectra (105.2 MHz) of 4 mM PDC-V(V) complex
in a medium containing 25 mM HEPES pH 7.0, 0.1 M KCl, 5 mM MgCl2,
in the absence (A) or in the presence of sarcoplasmic reticulum vesicles (5
mg/mL total protein (B) or 10 mg/mL (C).
Figure 4. 51V-NMR spectra (105.2 MHz), at 22 °C, of 9.0 mM
[VO2(ma)2]- (V(V)-maltol) (A) in aqueous solution, 9.0 mM (B), and 4.0
mM (C) BMOV complex solution prepared in the reaction medium; the
spectra observed in (B) and (C) represent the oxidized forms of BMOV.
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consistent with formation of the most stable V(V)-maltol
complex near neutral pH.40
In addition to the major oxidation product of BMOV,
[VO2(ma)2]-, (at -495 ppm, a second signal near -509 ppm
is observed and attributed to [VO2(ma)(H2O)2] (Figure 4).
Equilibration of these two V(V)-maltol will cause some line
broadening between the signals, and the presence of the
paramagnetic BMOV in these solutions can further increase
the relaxation rates, which contributes to line broadening.
For comparison, the spectrum is shown of an aqueous
solution of [VO2(ma)2]- (part A of Figure 4), demonstrating
that less line broadening is in fact observed under the
conditions of the enzyme assay.
When the solution of [VO2(ma)2]- is placed in a micro-
emulsion (Figure 5), the signal is broadened. In addition to
the [VO2(ma)2]- signal, a signal for oxovanadates (∼ -555
ppm) appeared. This observation suggests that the stability
of [VO2(ma)2]- is lower in the microemulsions, and the
complex hydrolyzed to form both V4 and V5 oxovanadates.
Whether the V(V)-maltol complexes are similar to the
PDC-V(V) complex51 in ability to penetrate the lipid
interface can now be considered. As shown in Figure 5, both
the 51V (A) and the 1H (B) NMR signals shifted and
broadened in the microemulsion environment. In Table 1,
the line widths of the [VO2(ma)2]- signal for the correspond-
ing sizes of the RM are shown. The line width of the
[VO2(ma)2]- signal increases from 420 Hz in aqueous
solution at pH 7.6 to more than double in small RMs, and,
importantly, as the water pool of the RM increases the line
width of the complex approaches that in aqueous solution.
The 1H NMR spectra (part B of Figure 5) also show a
significant shift upon placement of [VO2(ma)2]- in the RM
and a small but continuous shift as the RM size decreases,
consistent with the increased interaction with the lipid
interface. The change in the line width is indicative of the
[VO2(ma)2]- complex being located in the water pool
possible closely associated with the lipid interface in these
structures and not as PDC-V(V), which penetrated into the
lipid portion of the interface. The large downfield changes
in the 1H NMR chemical shifts are in contrast to the small
upfield changes in the 51V chemical shifts. However, as
previously reported, the downfield 1H NMR shift is consistent
with interaction with the lipid interface,58,59 although we have
recently found some inconsistencies with these empirical
correlations.51 We conclude that our experiments in micro-
emulsions are consistent with PDC-V(V) penetrating the
lipid interface, whereas [VO2(ma)2]- is more associated with
the aqueous pool interface.
We conclude that the observed inhibition of the ATPase
is caused by solutions containing BMOV and two V(V)-
maltol complexes, and either of these complexes or a
combination thereof could be the inhibiting species of the
ATPase. Regardless of the differential affinity of these
complexes for lipids, because the PDC-V(V) and BMOV
systems have very similar affinity for the Ca2+-ATPase, and
PDC-V(V) and [VO2(ma)2]- have differential level of
penetration of the lipid interface in microemulsions, it follows
that the inhibiting species in the BMOV system for the Ca2+-
ATPase is not likely to be the [VO2(ma)2]- complex, the
BMOV oxidation product.
In contrast to the other two complexes investigated in this
study, the HAIDA-V(IV) solutions only contains the V(IV)
Figure 5. 51V (panel A) and 1H (panel B) NMR spectra of [VO2(ma)2]- in D2O/AOT/isooctane microemulsions with wo ) 12, 16, and 20. Stock [VO2(ma)2]-
solution was prepared from 60 mM of NaVO3 and 120 mM of maltol at pH 7.6. Reverse micelles were prepared by adding a calculated volume of pH-
adjusted aqueous stock solutions to a calculated volume of 0.2 M AOT stock solution in isooctane, followed by vortexing to yield an optically transparent
homogeneous solution.
Table 1. 51V NMR Parameters for [VO2(ma)2]- in Aqueous Solution
Prepared from 60 mM NaVO3 and 120 mM maltol at pH 7.6 and
Microemulsions size (D2O/AOT/Isooctane RMs) Prepared from 0.2 M
AOT in Isooctane as Described in Figure 5
w0a chemical shift (ppm) linewidth (Hz) rh (nm)b
stock -495.6 420 ( 3
20 -495.2 630 ( 6 12.5 ( 0.3
16 -495.2 732 ( 7 6.4 ( 0.4
12 -494.6 960 ( 12 5.7 ( 0.1
a w0 ) [H2O]/[surfactant]; this is a term used to describe the
microemulsions.46 b rh is the diameter of the reverse micelle measured using
DLS.46
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compound added to solutions, as confirmed by EPR spec-
troscopy (data not shown).28,41 No 51V NMR signal was
detected, consistent with all the vanadium remaining in the
form of the original V(IV) complex. This spectrum is
consistent with no observable oxidation to a vanadium(V)
complex under these assay conditions and is in agreement
with previous studies.29,30
Combined, these studies show that the calcium pump has
a great affinity for PDC-V(V) and BMOV. These com-
pounds are the most effective insulin-enhancing compounds
examined, and we point to the possibility that there is a
correlation between insulin-enhancing properties and inhibi-
tion of Ca2+-ATPase activity. However, more studies are
needed to substantiate such a hypothesis further. Because
these complexes are known to undergo hydrolytic and redox
chemistry under physiological conditions, such conversions
are anticipated under our experimental conditions. The
affinity of Ca2+-ATPase for the PDC-V(V) and BMOV
systems is similar to that reported previously for decavana-
date (V10), an oxovanadate species recently found to be
stabilized the calcium pump and also by actin.55 V10 also is
found to affect mitochondria at nanomolar concentrations
and induce changes in oxidative stress markers after in vivo
administration.11,55–57 The calcium pump has previously been
found to be inhibited by the vanadium citrate complex;25
however, the studies shown here demonstrate more potent
interactions with the PDC-V(V) and BMOV systems.
Recent studies demonstrated that the redox properties of the
vanadium complexes are important to their insulin-enhancing
action.16 The studies presented show that the greatest
inhibition is observed for vanadium compounds with greater
insulin-enhancing effects. Although a trend should be based
on investigation of more compounds, these observations are
consistent with the proposed modes of inhibition of the Ca2+-
ATPase by BMOV and PDC-V(V) involving the com-
pounds’ coordination chemistry.
Whether the vanadates act by forming a transition-state
complex or binding as a substrate analogue depends on the
specific enzyme.6 Many phosphorylases are inhibited by
vanadate, and the mode of inhibition is the formation of a
stable transition-state complex.26 ATPases that catalyze ATP
hydrolysis while translocating specific ions are referred to
as pumps. For these enzymes that are inhibited by vanadate,
the mechanism is through trapping the vanadate at the
phosphate site accompanied by slow release, assuring
reduced catalytic turnover and inhibition of the enzyme
activity.1–9,11 The SR Ca2+-ATPase catalysis proceeds
through a noncovalent phosphoenzyme intermediate as has
been observed for other ATPases and phosphorylases and
subsequent formation of a phosphorylenzyme intermediate
during ATP hydrolysis.10 In the absence of ATP and calcium,
for this ATPase vanadate is proposed to bind in the vicinity
of the aspartyl phosphate acceptor so as to block the active
site and thus prevent phosphoenzyme intermediate formation,
ultimately trapping the enzyme in the E2 conformation.9,11
Phosphorylation of the SR calcium pump by ATP, and
conversion to the E1-P conformation, decreases the affinity
of specific oxovanadates for the enzyme. This is consistent
with the vanadate binding sites being in the region of the
phosphorylation site.9,11 Other modes of action have been
reported such as vanadate binding in a manner similar to an
ATP analogue.6 Vanadium-containing complexes have the
potential to act through mechanisms similar to the simple
oxovanadates if they can hydrolyze to form oxovanadate
while in the presence of the enzyme.
Monomeric vanadate is not the only form of oxovanadates
that can interact with these enzymes.6 The interaction of
decavanadate with the Ca2+-ATPase has been reported, and
unlike vanadate, such inhibition is not affected by ATP or
Ca2+.11 Therefore, SR ATPase conformational changes in
the presence of vanadium species can explain why the
different affinities for the protein are observed. For mono-
meric vanadate, the E2 conformation of the calcium pump
is favorable; however, V10 appears to interact with either the
E1 or E1-P conformation.11 Moreover, it is known that
oxovanadates bind to enzymes surfaces with positive
charges,9,32 namely lysine and arginine residues, locking the
enzyme in a specific conformation and in such a manner
inhibiting the enzyme activity.32,56 In this work, we report
the inhibition of Ca2+-ATPase by three vanadium coordina-
tion complexes. Because all three complexes cause inhibition
of the calcium pump different from that of the simple
oxovanadates, these results suggest that their mode of action
is different than the uncomplexed vanadium.
Conclusions
A combination of inhibition studies, 51V NMR, and EPR
spectroscopy was used to determine the interaction of
vanadium complexes with the calcium pump. The effects of
three well-characterized complexes, the pyridine-2,6-dicar-
boxylatodioxovanadium(V) (PDC-V(V)), bis(maltolato)ox-
ovanadium(IV) (BMOV), and bis(N-hydroxylamidoimino-
diacetato)vanadium(IV) (HAIDA-V(IV)), on SR preparations
of the calcium pump from sarcoplasmic reticulum were
determined. Because BMOV partially oxidizes into vanadi-
um(V) species, and the PDC-V(V) complex in part hydro-
lyzes into different amounts of monomeric (V1); dimeric (V2)
and tetrameric (V4) species, the complexes were monitored
in the enzyme assay medium. Because of the chemistry of
the chosen insulin-enhancing compounds under physiological
conditions, a third complex that is expected to be more
resistant to the reaction conditions, HAIDA-V(IV), was also
investigated. The order of the inhibition of the calcium
ATPase activity by the complexes is PDC-V(V) g BMOV
> HAIDA-V(IV), with IC50 values of 25 µM, 40 µM, and
325 µM, respectively. These affinities are much greater than
(55) Ramos, S; Manuel, M; Tiago, T.; Duarte, R.; Martins, J. A.; Gutierrez-
Merino, C. J.; Moura, J. J. G.; Aureliano, M. J. Inorg. Biochem. 2006,
100, 1734–1743.
(56) Aureliano, M.; Soares, S. S.; Tiago, T.; Ramos, S.; Gutierrez-Merino,
C. In Vanadium: The Versatile Metal; Kustin, K., Pessoa, J. C., Crans,
D. C., Eds., ACS Symposium Series, Vol. 974, Chapter 18, 249-263.
American Chemical Society, Washington, DC, 2007.
(57) Soares, S. S.; Henao, F.; Aureliano, M.; Gutierrez-Merino, C. Chem.
Res. Toxicol. 2008, 21, 607–618.
(58) Vermathen, M.; Chodosh, A. B.; Louis, E. A.; Simonis, U. J. Inorg.
Biochem. 1999, 74, 328.
(59) Vermathen, M.; Chodosh, A. B.; Ried, S.; Simonis, U. Langmuir 2000,
16, 210–221.
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the effects of the vanadium citrate complex that inhibits the
calcium ATPase activity with an IC50 of 0.5 mM.25 For
comparison, a vanadate solution (prepared from metavana-
date) has an IC50 of 80 µM. It is important to note that the
most potent inhibition was observed for the complexes that
can undergo oxidative or hydrolytic reactions under the
conditions of the assay, whereas the HAIDA-V(IV) complex
is a much less effective inhibitor. These observations are
significant because these compounds and their differential
inhibitory activities may serve as useful probes for unrav-
elling complex catalytic details for the Ca2+-ATPases.
Because the PDC-V(V) and BMOV complexes convert into
other species under the assay conditions, the presence of the
complexes in the assay medium was monitored. The target
compounds and other decomposition compounds were observed
in the medium. Because the complexes convert into other
species in the reaction medium and none of these species are
more potent than these coordination complexes, the simple
oxovanadate decomposition products are not causing most of
the inhibition. The well-known inhibition of phosphorylases by
vanadate through formation of a transition-state analogue
generally involves a covalent complex. Thus, in many cases,
such observations can readily be attributed to the hydrolysis of
such complexes to simple vanadate. The studies presented here
deviate from this description in that two of the coordination
complexes, PDC-V(V) and BMOV, are more potent than the
simple oxovanadate, monomeric vanadate. Because no decom-
position products were observed for the HAIDA-V(IV)
complex, the observed inhibition can be attributed exclusively
to this complex. Importantly, this coordination complex was
less effective than oxovanadate in inhibiting the calcium pump.
Because Ca2+-ATPase can adopt several conformations,
the specific nature of the interactions of each of the vanadium
species with the sarcoplasmic reticulum Ca2+-ATPase is
beyond the scope of this investigation. However, inhibition
by BMOV and PDC-V(V) was unchanged by ATP or Ca2+,
two effectors of enzyme in the E1 and E1-P conformation,
indicating a very different mode of action from that of
vanadate. These insulin-enhancing complexes that readily
undergo hydrolytic reactions were found to be more potent
inhibitors than the simple salt (vanadate). In contrast, the
HAIDA-V(IV) complex is a less-potent inhibitor. These
facts are consistent with the inhibition of the Ca2+-ATPase
by the vanadium compounds and involve adduct formation
between protein and the vanadium compound. These findings
are also consistent with the mechanism of the inhibition by
vanadate being through complexation of the vanadium atom
to the catalytic site of Ca2+-ATPase.
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